Inactive Instrument

Press Releases Rezolute Inc Other OTC

Equities

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

REZOLUTE, INC. - PHASE 2 RIZE STUDY SUB-ANALYSES TO BE PRESENTED AT THE 2024 PEDIATRIC ENDOCRINE SOCIETY ANNUAL MEETING	Apr. 24	AQ
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting	Apr. 23	GL
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting	Apr. 23	AQ
REZOLUTE REPORTS VALIDATION OF THE POTENTIAL USE OF RZ358 FOR TREATMENT OF NON-ISLET CELL TUMOR HYPOGLYCEMIA	Mar. 07	AQ
Rezolute : Corporate Presentation – March 2024	Mar. 06	PU
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)	Mar. 06	GL
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)	Mar. 06	AQ
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update	Feb. 13	GL
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer	Jan. 24	GL
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer	Jan. 24	AQ
REZOLUTE RECEIVES INNOVATION PASSPORT DESIGNATION FROM THE U.K. INNOVATIVE LICENSING AND ACCESS PATHWAY STEERING GROUP FOR RZ358	Jan. 24	AQ
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism	Jan. 23	GL
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism	Dec. 14	GL
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)	Dec. 13	GL
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"	Nov. 24	NE
REZOLUTE TO PARTICIPATE IN BTIG'S 3RD ANNUAL OPHTHALMOLOGY DAY	Nov. 20	AQ
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day	Nov. 17	GL
Rezolute Reports First Quarter Fiscal 2024 Results	Nov. 13	GL
REZOLUTE RECEIVES PRIORITY MEDICINES ELIGIBILITY FROM EUROPEAN MEDICINES AGENCY FOR ENHANCED REGULATORY SUPPORT OF RZ358 IN CONGENITAL HYPERINSULINISM	23-10-18	AQ
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism	23-10-17	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Rezolute Inc Other OTC

Equities

Press Releases

Filters